VERACYTE, INC. (VCYT): M&A transaction — Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M

VERACYTE, INC.

Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.
Up to $25M in additional milestone payments payable in cash or stock over next two years.
Veracyte to issue up to 2,698,349 shares as stock consideration; cash in lieu for non-accredited investors.
SEC granted partial waiver from certain financial statement requirements under Rule 3-13.
Closing occurred on February 5, 2024; audited C2i financials to be filed within 71 days.

item 2.01 item 9.01 item 3.02

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

VERACYTE, INC. completed an acquisition involving C2i Genomics, Inc. for $70.0 million (closed 2024-02-05).

Action: acquisition
Counterparty: C2i Genomics, Inc.
Consideration: $70.0 million
Closing: 2024-02-05

Exact text from the filing

On February 5, 2024 (the “Closing Date”), Veracyte, Inc., a Delaware corporation (“Veracyte”), completed its previously announced acquisition of C2i Genomics, Inc., a Delaware corporation (“C2i Genomics”), for a purchase price of $70.0 million

View on SEC.gov

106 m&a transactions filed in the last 30 days. Browse all m&a transactions →

VERACYTE, INC. filing history →

Source: SEC EDGAR

accession 0001384101-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.